Organovo Holdings, Inc. has issued an investor presentation, which is now, (since 16th September), available 24/7 for 90 days.
Regenerative medicine company Organovo Holdings focuses on applying its NovoGen 3D-bio-printing technology to create human tissue on demand for medical and therapeutic applications: apps that are poised to change the face of the potentials of bio-med. The presentation was originally made on Sept. 12th. Investors may download shareholder materials from the “virtual trade booth” for the next three weeks.
You can find the presentation here.
Organovo (NYSE MKT: ONVO) designs and creates functional, three-dimensional human tissues for medical research and therapeutic applications. The Company is collaborating with pharmaceutical and academic partners to develop human biological disease models in three dimensions.
These 3D human tissues have the potential to accelerate the drug discovery process, enabling treatments to be developed faster and at lower cost. In addition to numerous scientific publications, their technology has been featured in The Wall Street Journal, Time Magazine, The Economist, and other outlets. Organovo is changing the shape of medical research and practice.
Organovo, formerly Real Estate Restoration & Rental, Inc., is a development-stage company. On December 28, 2011, Real Estate Restoration and Rental, Inc.’s (RERR) entered into an Agreement and Plan of Merger, pursuant to which RERR merged with its, wholly owned subsidiary, Organovo (Merger Sub).
On February 8, 2012, the Company merged with and into Organovo Acquisition Corp. (Acquisition Corp.), a wholly owned subsidiary of Organovo, with the Company surviving the merger as a wholly owned subsidiary of Organovo Holdings (the Merger). As a result of the Merger, Organovo acquired the business of Organovo, Inc.